Wednesday, May 18, 2022
wellness India Expo
Home Tags DCGI

Tag: DCGI

Bharat Biotech’s Covaxin gets emergency approval for 6-12 age group

Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study in children 2-18 years of age

Glenmark Specialty gets DCGI nod for Phase 1 clinical trial of...

GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology

World TB Day: TB Alliance expresses commitment to accessibility of TB...

The DCGI (Drug Controller General of India) approved TB drug, pretomanid, for conditional access under the National Tuberculosis Elimination Program (NTEP), can play a significant role towards elimination of highly drug-resistant TB in India

Biological E’s COVID-19 vaccine gets EUA nod for 12-18 years age...

The Drugs Controller General of India (DCGI) has already approved CORBEVAX for restricted use in emergency situation among adults on December 28, 2021

Bharat Biotech gets DCGI nod for Phase 3 clinical trials of...

The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country.

Covaxin gets nod for kids aged 2-18 years

The Subject Expert Committee (SEC) has given a nod for use of Covaxin for children in the 2-18 years age group

LifeCell’s therapy to treat COVID-19 patients gets DCGI nod for clinical...

New therapy derived from mesenchymal stem cells of the umbilical cord tissue set to treat patients suffering from COVID 19 pneumonia and acute respiratory distress.............................

India’s first mRNA-based Covid-19 vaccine gets DCGI nod for Phase II...

The trial for India’s first mRNA-based vaccine from Gennova Biopharmaceuticals was found to be safe in Phase I study. Post Drugs Controller General of India approval, Phase II and Phase III trials are to commence in early September, 2021......................

DCGI gives approval to anti-COVID drug ‘Colchicine’ for phase 2 clinical...

Drugs Controller General of India (DCGI) has given approval to a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in the improvement of clinical outcomes during the treatment of COVID-19 patients...........................

Biophore applies for DCGI emergency use approval of Aviptadil for COVID-19

Aviptadil has shown significant results in clinical trials against COVID-19. Biophore has developed both the API and the formulation in-house...........................